Fresenius SE & Co KGaA
FRE: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€19.00 | Qhfjjpb | Smxygynr |
Fresenius SE Earnings: Strong on Rising Medical Utilization and Operating Controls
Narrow-moat Fresenius SE turned in strong second-quarter results and highlighted that it expects to deliver results on the top end of its profit outlook range in 2024. At first glance, we do not plan to change our EUR 50 fair value estimate on these trends, but this operating momentum appears promising for the company's undervalued shares.